Anna L. de Goede

A phase I/IIa immunotherapy trial of HIV-1-infected patients with Tat, Rev and Nef expressing dendritic cells followed by treatment interruption

Sabine Allard, Brenda De Keersmaecker, Anna L. de Goede et al. · Clinical Immunology · 2011 · 118 citations

Primary Immunodeficiency, Human Retrovirus, Immunology +11

Blood-derived dendritic cell vaccinations induce immune responses that correlate with clinical outcome in patients with chemo-naive castration-resistant prostate cancer

Harm Westdorp, Jeroen H. A. Creemers, Inge M. van Oort et al. · Journal for ImmunoTherapy of Cancer · 2019 · 110 citations · Full text

What does cell therapy manufacturing cost? A framework and methodology to facilitate academic and other small-scale cell therapy manufacturing costings

Renske M.T. ten Ham, Anke M. Hövels, Jarno Hoekman et al. · Cytotherapy · 2020 · 60 citations · Full text

Adjuvant Dendritic Cell Vaccination in High-Risk Uveal Melanoma

Kalijn F. Bol, Thomas van den Bosch, Gerty Schreibelt et al. · Ophthalmology · 2016 · 47 citations · Full text

Vaccination, Melanoma, Immunology +4

Adjuvant dendritic cell therapy in stage IIIB/C melanoma: the MIND-DC randomized phase III trial

Kalijn F. Bol, Gerty Schreibelt, Martine Bloemendal et al. · Nature Communications · 2024 · 35 citations · Full text